NCT01497873View on ClinicalTrials.gov

A Randomized Study to Compare the Efficacy and Safety of Belotecan and Topotecan as Monotherapy for Sensitive-Relapsed Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

164

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

December 31, 2017

Study Completion Date

March 31, 2018

Conditions
Small Cell Lung Cancer
Interventions
DRUG

Topotecan

1.5 mg/m\^2 IV days 1, 2, 3, 4, 5 of each 21-day cycle until 6 cycle or more

DRUG

Belotecan

0.5 mg/m\^2 IV days 1, 2, 3, 4, 5 of each 21-day cycle until 6 cycle or more

Trial Locations (14)

Unknown

Chungbuk University Hospital, Daegu

Keimyung University Dongsan Center, Daegu

Asan Medical Center, Seoul

CHA Bundang Medical Center, Seoul

Chung-Ang University hospital, Seoul

Kyung Hee University Medical Hospital, Seoul

Seoul National University Boramae Medical Center, Seoul

Seoul National University Hospital, Seoul

Seoul St. Marys Hospital, Seoul

Seoul Veterans Hospital, Seoul

Yonsei Cancer Center, Seoul

Ajou University Hospital, Suwon

St. Vincents Hospital, Suwon

410-769

National Cancer Center, Goyang

Sponsors
All Listed Sponsors
lead

Chong Kun Dang Pharmaceutical

INDUSTRY

NCT01497873 - A Randomized Study to Compare the Efficacy and Safety of Belotecan and Topotecan as Monotherapy for Sensitive-Relapsed Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter